SHALBY Shalby Q4 FY25 results (Jan–Mar 2025) and concall
Shalby reported mixed results for Q4 FY25, with strong top-line growth driven by the MedTech and Sanar businesses, but significant pressure on profitability. Consolidated revenue grew 8.4% YoY to INR 270 crores, while EBITDA declined 40.3% YoY to INR 26.2 crores due to strategic investments in doctors and the implant business. The company expressed confidence in future growth, particularly from its MedTech segment and the Sanar hospital, expecting double-digit growth in the coming years.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 268 | 276 | 265 |
| EBITDA | 33 | 34 | 21 |
| Net profit | 2 | -3 | -12 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
